Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Analyte monitoring system and method

a monitoring system and analyte technology, applied in the field of analyte monitoring system and method, can solve the problems of increased risk of severe hypoglycemia in patients receiving intensive insulin therapy, increased risk of more severe hypoglycemia, and increased risk of hypoglycemia

Inactive Publication Date: 2008-03-13
ABBOTT DIABETES CARE INC
View PDF101 Cites 484 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The system achieves high accuracy, with over 80% of data points within clinically acceptable zones, enabling reliable management of diabetes without the need for frequent fingerstick measurements, and effectively reduces glycemic fluctuations and hypoglycemic events.

Problems solved by technology

However, the DCCT found that patients receiving intensive insulin therapy were at a threefold increased risk of severe hypoglycemia.
Patients adhering to intensive insulin therapy regimens were found to have lowered thresholds for activation of neurogenic warning systems and consequently were at increased risk for more severe hypoglycemic events.
The increased risk of hypoglycemia and the fear associated with patients' perception of that risk has been cited as the leading obstacle for patients to achieve the targeted glycemic levels (Cryer P E.
In addition to the problem of chronic hyperglycemia contributing to long-term complications and the problem of acute iatrogenic hypoglycemia contributing to short-term complications, recent research suggests that transient episodes of hyperglycemia can lead to a wide range of serious medical problems besides previously identified microvascular complications as well as macrovascular complications such as increased risk for heart disease.
However, the development of this technology has proceeded more slowly than anticipated.
For example, two recent comprehensive reviews of decades of research in the field cited the lack of accuracy and reliability as the major factor limiting the acceptance of this new technology as well as the development of an artificial pancreas (Chia, C. W. and Saudek, C. D., “Glucose sensors: toward closed loop insulin delivery” Endocrinol. Metab. Clin. N. Am., 33, 174-195, 2004; Hovorka, R.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Analyte monitoring system and method
  • Analyte monitoring system and method
  • Analyte monitoring system and method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] Before the various embodiments of the present disclosure is described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

[0025] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the present disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the present disclosure, subject to any specifically excluded limit in the stat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Devices and methods for monitoring an analyte are provided. Embodiments include continuous analyte sensors having a high degree of accuracy.

Description

RELATED APPLICATIONS [0001] This application claims priority under 35 USC § 119 to Provisional Application No. 60 / 804,170 filed Jun. 7, 2006 entitled “Analyte Monitoring”, and to Provisional Application No. 60 / 804,169 filed Jun. 7, 2006 entitled “Analyte Monitoring System” the disclosure of each of which are incorporated in their entirety by reference for all purposesBACKGROUND OF THE INVENTION [0002] The association of chronic hyperglycemia and the devastating long-term complications of diabetes was clearly established by the Diabetes Control and Complication Trial (DCCT) (The Diabetes Control and Complications Trial Research Group. “The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus” N Engl J Med 329: 978-986, 1993; Santiago J V “Lessons from the Diabetes Control and Complications Trial” Diabetes 1993, 42: 1549-1554). [0003] The DCCT found that in patients receiving intensive insulin th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61B5/00
CPCA61B5/14532A61B5/14546A61B5/1486A61M5/1723C12Q1/006G01N33/48792A61B5/1495A61B5/076A61B5/14865A61B5/7282A61B5/746A61B2562/125A61M2005/1726
Inventor MCGARRAUGH, GEOFFREY V.FELDMAN, BENJAMIN J.PEYSER, THOMAS A.MAZZA, JOHN C.GOODNOW, TIMOTHY T.REBRIN, KERSTIN
Owner ABBOTT DIABETES CARE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products